Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Study of TUR03 vs Soliris in Healthy Men
NCT05863442Phase 1Recruiting
- Sponsor
- Turgut Ardika
- Start
- Apr 2023
- Primary completion
- Jul 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of eculizumab biosimilar Turgut in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) (2 arms), sponsored by Turgut Ardika. Primary endpoint: PK similarity of TUR03 and Soliris following a single IV infusion. Started Apr 2023; status: recruiting.
02
Drugs
eculizumab biosimilar Turgut
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT05863442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05863442.